. 2018 Mar 19;75(6):738–745. doi: 10.1001/jamaneurol.2018.0118

Table 1. Demographic and CSF Biomarker Data of Patients of the Sporadic Autopsy Cohort by Neuropathological Group.

Clinical and Biofluid Feature	Mean (SD)
	Pure Cases			Mixed Cases; FTLD-AD (n = 14)
	AD (n = 89)	FTLD-Tau (n = 27)	FTLD-TDP (n = 13)	Mixed Cases; FTLD-AD (n = 14)
Age at onset, y	66.5 (9.7)	60.8 (8.9)^a	62.4 (8.5)	70.6 (8.5)^b
Age at death, y	75.9 (10.1)^b^,^c	68.4 (8.8)^a^,^d	68.4 (9)^d	79.2 (11.3)^b
Age at CSF measure, y	70.2 (9.5)	64.2 (9.4)^a	65.3 (7.6)^a	74.5 (10.1)^b^,^c
Time from onset to CSF measure, y	3.72 (2.4)	3.41 (2)	2.92 (1.7)	3.9 (3.1)
Men, No. (%)	50 (56.8)	15 (65.2)	4 (33.3)	8 (57.1)
APOE ε4 positive, No. (%)	56 (63.6)	4 (17.4)^d	4 (33.3)	5 (37.5)
CSF Aβ_1-42 (n = 123)	137.8 (50.6)^b	244.1 (46.1)^a^,^d	216.8 (63.3)^a	148.7 (29.7)^b^,^c
CSF t-tau (n = 143)	120.3 (88)^b	48 (22.7)^d	54.1 (39.1)	65.6 (46.1)
CSF p-tau (n = 139)	41.1 (30.3)^b^,^c	11.9 (3.8)^a^,^c^,^d	7.9 (5.4)^a^,^b^,^d	17.7 (8.6)^b^,^c
CSF t-tau/Aβ_1-42 (n = 143)	1.01 (0.91)^b^,^c^,^a	0.20 (0.12)^d	0.26 (0.2)^d	0.44 (0.29)^d
CSF p-tau/Aβ_1-42 (n = 122)	0.34 (0.26),^a^,^b^,^c	0.05 (0.02)^a^,^d	0.04 (0.03)^a^,^d	0.14 (0.06)^b^,^c^,^d

Abbreviations: Aβ_1-42, amyloid β_1-42; AD, Alzheimer disease; CSF, cerebrospinal fluid; FTLD, frontotemporal lobar degeneration; p-tau, phosphorylated tau; t-tau, total tau.

^{^a}

P < .05 compared with AD-FTLD.

^{^b}

P < .05 compared with FTLD-Tau.

^{^c}

P < .05 compared with FTLD-TDP.

^{^d}

P < .05 compared with AD.